Add-on buprenorphine to ease suicidal thoughts in depression
Treatments studied
Part of Mental health clinical trials.
This Phase 3 study tests whether adding buprenorphine to your usual pain-dose medicines can reduce severe suicidal thoughts during a major depressive episode. It may help people who are currently hospitalized or closely followed and have higher scores for both depression severity and suicidal thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You are in the hospital or being followed by a clinic/doctor’s visits
- You have a current major depressive episode without psychosis
- Your depression severity and suicidal-thought scores are above study cutoffs
- You agree to informed consent and can sign it
- You are not already in another drug study and are not in a study “cooling-off” period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if ketamine can help reduce suicidal thoughts in people with major depression. You'll receive ketamine treatment and be monitored closely.
This study is testing whether adding a medication (buprenorphine), counseling, and a type of brain stimulation (TMS) can improve long-term opioid therapy for chronic pain. If you have been taking prescription opioids daily for at least 3 months and have extra risk factors for opioid-related problems, this trial may offer you new ways to manage pain and reduce risks.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This study tests whether low-dose buprenorphine can improve social motivation in people with schizophrenia. It compares social motivation changes while keeping participants stable on treatment and avoiding certain medicines and substances.
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
Hear when a new Suicidal Ideation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.